Nerve conduction studies, statokinesigraphy, Rankin scale, and status of Sjögren’s syndrome before and after interferon alfa treatment
| Variable | Patient 1 | Patient 2 | Patient 3 | |||
|---|---|---|---|---|---|---|
| Before Rx | After Rx | Before Rx | After Rx | Before Rx | After Rx | |
| *Temporal dispersion was observed. | ||||||
| †Statokinesigram4: total movement length of the gravity centre with eyes opened/closed during 30 seconds, n = 6 (mean (SD)). | ||||||
| ‡Modified Rankin scale: 0, no symptoms at all; 1, no significant disability, able to carry out all usual duties and activities; 2, slight disability, unable to carry out delicate tasks but able to look after own affairs without assistance; 3, moderate disability, requiring some help, but able to walk without assistance; 4, moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance; 5, severe disability, bedridden. | ||||||
| §Sensory ataxia scale3: 0, normal ability to stand on one foot with eyes closed; 1, stands/walks normally with eyes closed; 2, stands/walks with minor swaying with eyes closed but normally with eyes open; 3, stands/walks with some swaying with eyes open; 4, stands/walks on a large base with eyes open; 5, standing/walking impossible without support. | ||||||
| ¶Items in the revised Euro-criteria for Sjögren’s syndrome are: I, ocular symptoms; II, oral symptoms; III, ocular signs (positive Schirmer’s test); IV, histopathological features; V, salivary gland involvement; VI, autoantibodies to SS-A or SS-B. | ||||||
| **Normative value for anti-SS-A/SS-B antibody titres in ELISA are <10/<15, respectively. | ||||||
| ††Daniels focus score6: grade is based on infiltrate of lymphocytes, plasma cells, and macrophages per 4 mm2 area of salivary tissue: grade 0, absent; grade 1, slight infiltrate; grade 2, moderate infiltrate, less than one focus; grade 3, one focus; grade 4, two or more foci. Focus score (extension of grade 4), 2–10: number of foci of >50 mononuclear cells per 4 mm2 area of salivary gland. | ||||||
| NP, not performed; Rx, treatment with IFNα. | ||||||
| Motor conduction | ||||||
| R median amplitude (mV)/CV (m/s) | 4.8/56 | 4.7/58 | 10.6/55 | 12.9/53 | 3.1/35 | 3.8/42 |
| R ulnar amplitude (mV)/CV (m/s) | 7.8/47 | 8.0/48 | 7.2/44 | 7.0/47 | 10.5/38 | 11.6/40 |
| R tibial amplitude (mV)/CV (m/s) | 5.8/43 | 6.8/46 | 5.2/31 | 4.9/31 | 12.1/28* | 11.6/35* |
| Sensory conduction | ||||||
| R median amplitude (μV)/CV (m/s) | 11.6/55 | 11.6/52 | 39.8/45 | 41.3/40 | 10.3/37 | 12.4/36 |
| R ulnar amplitude (μV)/CV (m/s) | 13.0/51 | 14.0/48 | 11.2/40 | 15.8/48 | 11.6/22 | 12.7/32 |
| R sural amplitude (μV)/CV (m/s) | 0.2/48 | 8.9/45 | 1.2/51 | 10.6/48 | 12.9/40 | 10.6/48 |
| Statokinesigram (cm)† | 217.7 (28.3)/ 346.3 (62.9) | 72.5 (10.8)/ 195.8 (12.5) | 125.5 (12.9)/ NP | 7.79 (0.64)/ NP | NP | NP |
| Modified Rankin scale‡ | 2–3 | 1 | 2–3 | 1 | 2–3 | 0 |
| Sensory ataxia scale§ | 5 | 3 | 5 | 2 | 2 | 1 |
| Positive items for SS¶ | I, II, III, IV, VI | II | I, II, IV, VI | II, IV | I, II, IV, VI | none |
| Anti-SS-A/SS-B antibody titres** | 42.0/18.0 | 9.1/9.2 | 47.1/32.0 | 8.8/9.3 | 47.0/8.2 | 3.1/2.6 |
| Schirmer’s test (right/left, mm) | 3/5 | 18/14 | 12/16 | 19/22 | 16/9 | 14/35 |
| Daniels focus score (grade/focus)†† | 3/0 | 2/0 | 4/3 | 3/0 | 4/3 | 2/0 |